Brand Name | Status | Last Update |
---|---|---|
epoch | OTC monograph not final | 2022-01-12 |
epoch ava puhi moni anti-dandruff | OTC monograph final | 2022-01-12 |
epogen | Biologic Licensing Application | 2018-07-25 |
mircera | Biologic Licensing Application | 2023-10-12 |
procrit | Biologic Licensing Application | 2023-11-01 |
retacrit | Biologic Licensing Application | 2023-06-08 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Anemia | D000740 | HP_0001903 | D64.9 | 11 | 103 | 128 | 68 | 49 | 351 |
Chronic renal insufficiency | D051436 | — | N18 | 8 | 24 | 27 | 10 | 19 | 87 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 7 | 21 | 18 | 12 | 11 | 66 |
Neoplasms | D009369 | — | C80 | 1 | 14 | 14 | 5 | 11 | 45 |
Myelodysplastic syndromes | D009190 | — | D46 | 2 | 21 | 11 | 2 | 5 | 38 |
Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 2 | — | 4 | 8 | 15 |
Lymphoma | D008223 | — | C85.9 | 1 | 3 | 7 | 1 | 2 | 14 |
Iron-deficiency anemia | D018798 | HP_0001891 | D50 | 1 | 2 | 3 | 4 | 5 | 14 |
Renal insufficiency | D051437 | HP_0000083 | N19 | — | 2 | 4 | 1 | 2 | 8 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 6 | 1 | — | 8 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 16 | 3 | 1 | — | 4 | 22 |
Leukemia | D007938 | — | C95 | — | 5 | 7 | — | 1 | 13 |
Traumatic brain injuries | D000070642 | — | S06 | — | 5 | 4 | — | 1 | 8 |
Plasma cell neoplasms | D054219 | — | — | — | 2 | 5 | — | 1 | 8 |
Multiple myeloma | D009101 | — | C90.0 | — | 1 | 3 | — | 3 | 7 |
Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 4 | 2 | — | 1 | 7 |
Cerebral palsy | D002547 | — | G80 | 1 | 2 | 1 | — | 3 | 7 |
Brain hypoxia-ischemia | D020925 | EFO_1000846 | P91.6 | 4 | 3 | 3 | — | — | 7 |
Acute kidney injury | D058186 | HP_0001919 | N17 | — | 4 | 2 | — | 2 | 7 |
Blood transfusion | D001803 | — | — | — | 4 | 5 | — | 1 | 7 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 5 | — | — | — | 5 |
Ischemic stroke | D000083242 | — | — | 3 | 2 | — | — | — | 4 |
Sickle cell anemia | D000755 | EFO_0000697 | D57 | 2 | 1 | — | — | 1 | 3 |
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 2 | — | — | 1 | 3 |
Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 1 | 2 | — | — | 1 | 3 |
Critical illness | D016638 | — | — | — | 2 | — | — | 1 | 3 |
Friedreich ataxia | D005621 | Orphanet_95 | G11.11 | — | 3 | — | — | — | 3 |
Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | 1 | — | — | — | 2 |
Retinopathy of prematurity | D012178 | EFO_1001158 | H35.1 | 1 | 1 | — | — | 1 | 2 |
Reperfusion injury | D015427 | — | — | — | 1 | — | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | 2 | 3 |
Reticulocyte count | D017701 | — | — | 1 | — | — | — | — | 1 |
Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | — | — | — | — | 1 |
Autoimmune hepatitis | D019693 | — | K75.4 | 1 | — | — | — | — | 1 |
Hypogonadism | D007006 | HP_0000044 | E23.0 | 1 | — | — | — | — | 1 |
Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | — | — | — | — | 1 |
Alveolar bone loss | D016301 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Diabetic retinopathy | D003930 | EFO_0003770 | — | — | — | — | — | 2 | 2 |
Surgical blood loss | D016063 | — | — | — | — | — | — | 2 | 2 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 2 | 2 |
Sepsis | D018805 | HP_0100806 | A41.9 | — | — | — | — | 2 | 2 |
Continuous ambulatory peritoneal dialysis | D010531 | — | — | — | — | — | — | 1 | 1 |
Developmental disabilities | D002658 | EFO_0003852 | F89 | — | — | — | — | 1 | 1 |
Iron metabolism disorders | D019189 | — | E83.1 | — | — | — | — | 1 | 1 |
Hemolytic anemia | D000743 | — | D55-D59 | — | — | — | — | 1 | 1 |
Vitamin b 12 deficiency | D014806 | EFO_0000734 | E53.8 | — | — | — | — | 1 | 1 |
Arthroplasty | D001178 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Epoetin beta |
INN | epoetin alfa |
Description | Epoetin beta (INN), sold under the brand name Neorecormon among others, is a synthetic, recombinant form of erythropoietin, a protein that promotes the production of red blood cells. It is an erythropoiesis-stimulating agent (ESA) that is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy.
|
Classification | Protein |
Drug class | erythropoietins |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 122312-54-3 |
RxCUI | 105695 |
ChEMBL ID | CHEMBL2109092 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB00016 |
UNII ID | 64FS3BFH5W (ChemIDplus, GSRS) |